The Man Behind the Breast Cancer Breakthrough: Doctor Dennis Slamon's Groundbreaking Work We weren’t able to create a summary for you. Refresh your page to try again. Slamon spoke with Denise Heady, science communications and media relations manager for the UCLA Health Jonsson Comprehensive Cancer Center, about the paradigm-shifting approach to cancer treatment and how the discovery has opened up an entirely new area of research. Slamon spoke with Denise Heady, science communications and media relations manager for the UCLA Health Jonsson Comprehensive Cancer Center, about the paradigm-shifting approach to cancer treatment and how the discovery has opened up an entirely new area of research. Dennis Joseph Slamon (born August 6, 1948), [1][2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab. Dennis Joseph Slamon (born August 6, 1948), [1][2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.
